Bio-Imaging Technologies put Adeoye Olukotun on its board of directors. Olukotun is the co-founder and chief medical officer of VIA Pharmaceuticals, a publicly traded biotechnology company focused on the treatment of cardiovascular disease based in San Francisco, California. “We are very pleased to have Oye join our board of directors,” said David Nowicki, chairman of the board of directors of Bio-Imaging Technologies. “He brings deep experience in drug development to our board, which complements the board’s leadership in guiding the company’s future growth strategy and shareholder value creation.”

BioReliance Corporation appointed James Kramer VP of global biologics operations. He’ll overseee three company facilities in Scotland, located in Glasgow, Stirling and Edinburgh. “Jim is an excellent choice to lead our global biologics operations as we aggressively proceed in developing our organization to more effectively serve our clients,” said David Dodd, president and CEO. Here’s the release.

Clinilabs provided centralized data processing services to Vanda Pharmaceuticals for a Phase III study of an investigational drug for the treatment of sleep disorders. During this multi-center, placebo-controlled, randomized trial, 322 subjects with chronic primary insomnia received either tasimelteon or placebo over a four-week period. “It was our pleasure to work with Vanda,” stated Gary Zammit, president and CEO of Clinilabs.

ProTrials Research earned a spot on the 2008 Inc. 5000 list of the fastest-growing private companies in the U.S. With 125 percent sales growth over the last three years, ProTrials came in at number 2,858. “Our ranking on this prestigious list for the second straight year was a direct result of the unrivaled service we provide our customers,” said Jodi Andrews, ProTrials co-founder and CEO. “Because we are hired clinical trial help, the recent revenue increase we’ve witnessed at ProTrials is a testament to the quality of work we provide and the relationships we’ve built with our clients.” Companies on the Inc. list are U.S.-based, privately held, independent—not subsidiaries or divisions of other companies—and able to demonstrate $200,000 in revenue in 2004, and $2 million in 2007. Here’s the release.

Following the acquisition of Drug Development Solutions (DDS) in February, Chiltern announced that it has fully integrated its two early-phase units into a single operation. Chiltern Early Phase relies on units in Slough, U.K., (just outside of London) and Dundee, Scotland. With 72 beds, the unit can cover all therapeutic areas and all types of clinical pharmacology studies, with specialization in first in man, photosensitivity, drug-drug interaction, Japanese bridging and vaccine studies. Glenn Kerkhof, CEO of Chiltern, said, “Our vision was to develop a brand that would be synonymous with quality and service excellence. We now have the team, organization and facilities to deliver on this vision.”

PHT, a provider of electronic patient-reported outcome (ePRO) solutions, announced that the Clinical Data Interchange Standards Consortium (CDISC) has certified its StudyWorks program as compliant to a key data standard. StudyWorks is a web-based program for viewing, managing and exporting ePRO data. PHT is the only handheld patient diary provider to achieve CDISC Operational Data Model (ODM) certification. “As a founding member of CDISC, PHT strongly believes in the importance of using standards for clinical research data interchange,” said Phil Lee, PHT president and CEO. “We invested in the CDISC certification because of the value it adds to our clients. Trial sponsors know that seamless data integration with other eclinical systems is yet another advantage to working with PHT.” Here’s the release. The company’s annual user meeting in October is open to the industry; you can find more information here.
Have a news release? Send it to .